TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 46
4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50
5 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51
6 MARKET OVERVIEW 54
6.1 DRIVERS 56
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58
6.2 RESTRAINTS 59
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
6.4.1 PRODUCT RECALLS 63
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63
7 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64
7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69
8 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71
8.1 OVERVIEW 72
8.2 VIRAL 75
8.2.1 CORONAVIRUS 76
8.2.2 INFLUENZA VIRUS 76
8.2.3 ADENOVIRUS 76
8.2.4 RHINOVIRUS 76
8.2.5 ROTAVIRUS 76
8.2.6 OTHERS 76
8.3 BACTERIAL 77
8.3.1 PNEUMONIAE 78
8.3.2 BORDETELLA PERTUSSIS 78
8.3.3 STAPHYLOCOCCUS 78
8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79

9 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81
9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89
10 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91
10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99
11 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100
11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107
12 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108
12.1 MIDDLE EAST AND AFRICA 109
12.1.1 SOUTH AFRICA 116
12.1.2 SAUDI ARABIA 119
12.1.3 U.A.E 122
12.1.4 ISRAEL 125
12.1.5 EGYPT 128
12.1.6 REST OF MIDDLE EAST AND AFRICA 131
13 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 132
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 132
14 SWOT ANALYSIS 133
15 COMPANY PROFILE 134
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMRIEUX SA) 134
15.1.1 COMPANY SNAPSHOT 134
15.1.2 REVENUE ANALYSIS 134
15.1.3 COMPANY SHARE ANALYSIS 135
15.1.4 PRODUCT PORTFOLIO 135
15.1.5 RECENT DEVELOPMENTS 136
15.2 F. HOFFMANN-LA ROCHE LTD 137
15.2.1 COMPANY SNAPSHOT 137
15.2.2 REVENUE ANALYSIS 137
15.2.3 COMPANY SHARE ANALYSIS 138
15.2.4 PRODUCT PORTFOLIO 138
15.2.5 RECENT DEVELOPMENT 139
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 140
15.3.1 COMPANY SNAPSHOT 140
15.3.2 RECENT FINANCIALS 140
15.3.3 COMPANY SHARE ANALYSIS 141
15.3.4 PRODUCT PORTFOLIO 141
15.3.5 RECENT DEVELOPMENT 142
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 143
15.4.1 COMPANY SNAPSHOT 143
15.4.2 RECENT FINANCIALS 143
15.4.3 COMPANY SHARE ANALYSIS 144
15.4.4 PRODUCT PORTFOLIO 144
15.4.5 RECENT DEVELOPMENTS 145
15.5 QIAGEN 146
15.5.1 COMPANY SNAPSHOT 146
15.5.2 RECENT FINANCIALS 146
15.5.3 COMPANY SHARE ANALYSIS 147
15.5.4 PRODUCT PORTFOLIO 147
15.5.5 RECENT DEVELOPMENT 147

15.6 ABBOTT 148
15.6.1 COMPANY SNAPSHOT 148
15.6.2 REVENUE ANALYSIS 148
15.6.3 PRODUCT PORTFOLIO 149
15.6.4 RECENT DEVELOPMENT 149
15.7 AKONNI BIOSYSTEMS, INC. 150
15.7.1 COMPANY SNAPSHOT 150
15.7.2 PRODUCT PORTFOLIO 150
15.7.3 RECENT DEVELOPMENT 150
15.8 APPLIED BIOCODE, INC. 151
15.8.1 COMPANY SNAPSHOT 151
15.8.2 PRODUCT PORTFOLIO 151
15.8.3 RECENT DEVELOPMENTS 152
15.9 BD 153
15.9.1 COMPANY SNAPSHOT 153
15.9.2 REVENUE ANALYSIS 153
15.9.3 PRODUCT PORTFOLIO 154
15.9.4 RECENT DEVELOPMENTS 154
15.10 BIOCARTIS 155
15.10.1 COMPANY SNAPSHOT 155
15.10.2 REVENUE ANALYSIS 155
15.10.3 PRODUCT PORTFOLIO 156
15.10.4 RECENT DEVELOPMENT 156
15.11 BIO-RAD LABORATORIES, INC. 157
15.11.1 COMPANY SNAPSHOT 157
15.11.2 REVENUE ANALYSIS 157
15.11.3 PRODUCT PORTFOLIO 158
15.11.4 RECENT DEVELOPMENT 158
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 159
15.12.1 COMPANY SNAPSHOT 159
15.12.2 REVENUE ANALYSIS 159
15.12.3 PRODUCT PORTFOLIO 160
15.12.4 RECENT DEVELOPMENT 160
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 161
15.13.1 COMPANY SNAPSHOT 161
15.13.2 RECENT FINANCIALS 161
15.13.3 PRODUCT PORTFOLIO 162
15.13.4 RECENT DEVELOPMENTS 162

15.14 HOLOGIC, INC. 163
15.14.1 COMPANY SNAPSHOT 163
15.14.2 RECENT FINANCIALS 163
15.14.3 PRODUCT PORTFOLIO 164
15.14.4 RECENT DEVELOPMENT 164
15.15 MIRXES PTE LTD. 165
15.15.1 COMPANY SNAPSHOT 165
15.15.2 PRODUCT PORTFOLIO 165
15.15.3 RECENT DEVELOPMENT 165
15.16 NANMIX, INC. 166
15.16.1 COMPANY SNAPSHOT 166
15.16.2 PRODUCT PORTFOLIO 166
15.16.3 RECENT DEVELOPMENT 166
15.17 PROMINEX INC. 167
15.17.1 COMPANY SNAPSHOT 167
15.17.2 PRODUCT PORTFOLIO 167
15.17.3 RECENT DEVELOPMENT 167
15.18 QUANTUMDX GROUP LTD. 168
15.18.1 COMPANY SNAPSHOT 168
15.18.2 PRODUCT PORTFOLIO 168
15.18.3 RECENT DEVELOPMENTS 168
15.19 SEEGENE INC. 169
15.19.1 COMPANY SNAPSHOT 169
15.19.2 REVENUE ANALYSIS 169
15.19.3 PRODUCT PORTFOLIO 170
15.19.4 RECENT DEVELOPMENTS 173
15.20 SIEMENS HEALTHCARE GMBH 174
15.20.1 COMPANY SNAPSHOT 174
15.20.2 RECENT FINANCIALS 174
15.20.3 PRODUCT PORTFOLIO 175
15.20.4 RECENT DEVELOPMENT 175
15.21 THERMOFISHER SCIENTIFIC INC. 176
15.21.1 COMPANY SNAPSHOT 176
15.21.2 RECENT FINANCIALS 176
15.21.3 PRODUCT PORTFOLIO 177
15.21.4 RECENT DEVELOPMENT 177
16 QUESTIONNAIRE 178
17 RELATED REPORTS 181

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.